-+ 0.00%
-+ 0.00%
-+ 0.00%

Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032

PUBT·09/23/2026 20:35:12
Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032
  • Viking Therapeutics launched a public offering of USD 200 million convertible senior notes due 2032.
  • Underwriters hold a 30-day option to buy up to an additional USD 30 million of the notes for over-allotments.
  • Notes to mature Oct. 15, 2032; senior unsecured; interest payable semi-annually; conversion settled in cash, shares, or both.
  • Redemption allowed from Oct. 22, 2029 if shares trade above 130% of the conversion price for a specified period.
  • Proceeds earmarked for development and commercialization of VK2735, advancement of VK3019, working capital, and general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609231632PR_NEWS_USPR_____LA55581) on September 23, 2026, and is solely responsible for the information contained therein.